GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lepu Medical Technology (Beijing) Co 300003.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

12.40

-1.67%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥6.48bn

FY2016FY2025

Net income

CN¥962.0m

FY2016FY2025

Free cash flow

CN¥873.9m

FY2016FY2025

Shareholders' equity

CN¥16.12bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥6.48bnCN¥6.10bnCN¥7.98bnCN¥10.61bnCN¥10.66bnCN¥8.04bnCN¥7.80bnCN¥6.36bnCN¥4.54bnCN¥3.47bn
Gross profitCN¥4.15bnCN¥3.55bnCN¥5.00bnCN¥6.59bnCN¥6.49bnCN¥5.38bnCN¥5.62bnCN¥4.62bnCN¥3.05bnCN¥2.11bn
Research and developmentCN¥792.4mCN¥769.6mCN¥879.4mCN¥957.1mCN¥907.9mCN¥736.1mCN¥543.9mCN¥376.2mCN¥234.7mCN¥168.6m
Operating incomeCN¥1.54bnCN¥253.1mCN¥1.59bnCN¥2.62bnCN¥2.32bnCN¥2.08bnCN¥2.20bnCN¥1.68bnCN¥1.25bnCN¥924.9m
Net incomeCN¥962.0mCN¥246.9mCN¥1.26bnCN¥2.20bnCN¥1.72bnCN¥1.80bnCN¥1.73bnCN¥1.22bnCN¥899.1mCN¥679.3m
Diluted earnings per share0.520.130.681.160.961.010.980.680.500.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥26.14bnCN¥24.57bnCN¥25.02bnCN¥24.48bnCN¥20.70bnCN¥18.26bnCN¥15.93bnCN¥15.10bnCN¥12.79bnCN¥9.50bn
Cash and short-term investments—CN¥3.99bnCN¥4.50bnCN¥5.74bnCN¥3.86bnCN¥2.45bnCN¥1.96bnCN¥2.39bnCN¥2.45bnCN¥1.93bn
Total liabilitiesCN¥8.38bnCN¥7.83bnCN¥7.52bnCN¥8.11bnCN¥8.43bnCN¥7.72bnCN¥7.92bnCN¥8.53bnCN¥5.76bnCN¥3.49bn
DebtCN¥2.91bnCN¥4.18bnCN¥4.41bnCN¥2.78bnCN¥4.59bnCN¥4.34bnCN¥3.92bnCN¥5.10bnCN¥3.85bnCN¥1.97bn
Shareholders' equityCN¥16.12bnCN¥15.20bnCN¥15.98bnCN¥15.15bnCN¥11.47bnCN¥9.87bnCN¥7.48bnCN¥6.35bnCN¥6.43bnCN¥5.53bn
Shares outstanding1,843m1,846m1,858m1,894m1,790m1,777m1,769m1,781m1,782m1,744m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.52bnCN¥734.6mCN¥990.4mCN¥2.79bnCN¥3.06bnCN¥2.09bnCN¥1.99bnCN¥1.50bnCN¥913.1mCN¥691.9m
Capital spending−CN¥643.1m−CN¥658.8m−CN¥844.7m−CN¥905.2m−CN¥984.4m−CN¥600.1m−CN¥563.1m−CN¥1.07bn−CN¥716.1m−CN¥123.1m
Free cash flowCN¥873.9mCN¥75.8mCN¥145.7mCN¥1.89bnCN¥2.08bnCN¥1.49bnCN¥1.43bnCN¥428.6mCN¥197.0mCN¥568.8m
Dividends paid−CN¥681.5m−CN¥990.9m−CN¥635.1m−CN¥635.6m−CN¥587.0m−CN¥598.4m−CN¥639.2m−CN¥477.1m−CN¥281.7m−CN¥217.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.54bnCN¥1.67bnCN¥1.54bnCN¥1.57bnCN¥1.63bnCN¥1.74bnCN¥1.32bnCN¥1.40bn
Gross profitCN¥918.8mCN¥1.04bnCN¥978.5mCN¥1.01bnCN¥1.05bnCN¥1.11bnCN¥542.2mCN¥831.9m
Operating incomeCN¥265.3mCN¥421.8mCN¥206.6mCN¥353.7mCN¥371.7mCN¥468.4m−CN¥547.3mCN¥108.8m
Net incomeCN¥252.7mCN¥246.8m−CN¥20.0mCN¥291.1mCN¥312.4mCN¥378.5m−CN¥555.7mCN¥105.4m
Diluted earnings per share0.140.13-0.010.160.170.21-0.300.06
Cash from operations———CN¥425.0mCN¥217.0mCN¥419.0mCN¥311.0mCN¥264.0m
Capital spending−CN¥332.0m−CN¥248.0m−CN¥192.0m−CN¥145.0m−CN¥173.0m−CN¥131.0m−CN¥155.0m−CN¥129.0m
Free cash flow———CN¥280.0mCN¥44.0mCN¥288.0mCN¥156.0mCN¥135.0m
Total assetsCN¥26.17bnCN¥25.59bnCN¥26.14bnCN¥25.61bnCN¥25.36bnCN¥25.23bnCN¥24.57bnCN¥25.01bn
Cash and short-term investments———CN¥3.94bnCN¥3.80bnCN¥4.09bnCN¥3.99bnCN¥3.75bn
DebtCN¥3.60bnCN¥3.21bnCN¥2.91bnCN¥3.35bnCN¥2.60bnCN¥2.81bnCN¥3.93bnCN¥4.81bn
Shareholders' equityCN¥16.40bnCN¥16.44bnCN¥16.12bnCN¥16.03bnCN¥15.80bnCN¥15.62bnCN¥15.20bnCN¥15.80bn

Financial ratios

Data as of 21 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin64.0%58.1%62.6%62.1%60.9%66.9%
Operating margin23.7%4.1%20.0%24.7%21.8%25.8%
Net margin14.8%4.0%15.8%20.8%16.1%22.4%
Return on equity6.0%1.6%7.9%14.5%15.0%18.3%
Return on assets3.7%1.0%5.0%9.0%8.3%9.9%
Free cash flow yield10.0%6.5%8.5%16.7%19.3%13.0%
Revenue growth6.2%-23.5%-24.8%-0.5%32.6%3.1%
Earnings growth289.6%-80.4%-42.9%28.2%-4.6%4.4%
Current ratio2.01x2.34x2.48x2.02x2.44x1.36x
Debt to equity0.18x0.26x0.26x0.17x0.39x0.43x
Equity ratio61.7%61.9%63.8%61.9%55.4%54.1%
Interest coverage8.71x1.37x9.08x13.29x9.80x7.31x
R&D as a share of sales12.2%12.6%11.0%9.0%8.5%9.2%
Buybacks as a share of market value0.1%0.6%1.9%-5.8%-0.8%-0.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-15.1%-4.2%8.9%
Operating income-16.3%-5.8%8.4%
Net income-24.1%-11.8%6.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin61.2%61.9%62.5%64.3%
Operating margin14.2%19.3%20.9%22.9%
Net margin9.6%15.0%16.4%17.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings30.384.823.919.823.626.833.930.447.946.0
Price to sales4.53.43.84.13.86.07.55.89.59.0

Dividends and splits

Per share, in the currency the company pays

Paid for 16 years. Last went ex-dividend on 26 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.1630.2980.4730.3410.2750.2280.200.165
  • 2-for-1 split · 23 Jun 2016
  • 2-for-1 split · 18 May 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.